Ilya Gluhovsky and Paul Neyman join Liam on this week’s podcast episode. Ilya has an extensive background in software development, machine learning, and AI, with leadership roles in companies like Ancestry.com and Rally Health, and is now the co-founder of Areti Health, a company focused on revolutionizing patient recruitment in clinical trials using generative AI. Paul, with a background in computer science and sales, has successfully scaled multiple startups and now drives the sales strategy at Areti Health. In our discussion today, we dive into the challenges of patient recruitment in clinical trials, explore how generative AI is transforming the process, discuss the importance of personalized and culturally sensitive patient engagement, and uncover the future potential of AI in improving clinical trial efficiency and outcomes. We also touch on the misconceptions about AI in healthcare and a new standard for patient interaction and retention in clinical research, and much more.

Scott joins Liam on this week’s podcast episode. Scott has built an impressive career focused on patient recruitment and experience and DCT across several prominent companies, including Accenture, Verily, and also is a part of Decentralized Trials & Research Alliance (DTRA) as a Member Board of Directors. In our discussion today, we delve into a range of topics relating to recruitment and patient experience, we discuss what patient centricity means, explore how Scott would deliver clinical trials if he had a blank canvas, we explore what most people don’t know about patient recruitment and uncover what innovations Scott is most excited about and much more.

Sandy joins Liam on this week’s podcast episode. Sandy is the Vice President of Commercial Operations at MMS. Sandy has built an impressive career focused on strategic pricing across several prominent companies, including Syneos, PPD, Quintiles, and more. In our discussion today, we delve into a range of critical topics, including the distinction between price and value in the industry, what’s broken in the current trial model between sponsors, CROs, and sites, and why we shouldn’t rely on past pricing models to shape the future. Additionally, we explore Sandy's backstory on how she entered the clinical trials space, her unique process for helping groups demonstrate value over price, and much more.